lenvatinib + paclitaxel

Lenvatinib + paclitaxel is a combination regimen of two pharmaceutical agents used primarily in oncology. Lenvatinib is an oral, small molecule, multitargeted tyrosine kinase inhibitor that blocks the activity of several receptors involved in tumor angiogenesis and proliferation, including vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET proto-oncogene, and KIT proto-oncogene. Paclitaxel is a microtubule-stabilizing chemotherapeutic agent that inhibits cell division by promoting tubulin polymerization and preventing microtubule depolymerization. The combination has been investigated for synergistic antitumor effects in patients with recurrent endometrial cancer and platinum-resistant epithelial ovarian cancer. Clinical studies have shown encouraging response rates and manageable toxicity profiles for this regimen[1][2][5].